Variabilities of serum proteomic spectra in patients with gastric cancer before and after operation

Ren, Hong; Du, Ning; Zhang, Jing; Yao, Jia; Jing-sen, Shi

doi:10.11569/wcjd.v16.i3.314

Cited by 1 publication

(1 citation statement)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…ERp57 is also related to gastric cancer treatment. Clinical trials have shown that ERp57 levels in the serum of patients with gastric cancer are decreased significantly after surgical treatment [39]. Taken together, these studies demonstrate that ERp57 is associated with tumor initiation and development; however, the implication of ERp57 in cancer is still debated.…”

Section: Clinical Implications Of Erp57 In Cancermentioning

confidence: 90%

Insights into the role of ERp57 in cancer

Song¹,

Líu²,

Wu³

et al. 2021

J. Cancer

View full text Add to dashboard Cite

Endoplasmic reticulum resident protein 57 (ERp57) has a molecular weight of 57 kDa, belongs to the protein disulfide-isomerase (PDI) family, and is primarily located in the endoplasmic reticulum (ER). ERp57 functions in the quality control of nascent synthesized glycoproteins, participates in major histocompatibility complex (MHC) class I molecule assembly, regulates immune responses, maintains immunogenic cell death (ICD), regulates the unfolded protein response (UPR), functions as a 1,25-dihydroxy vitamin D3 (1,25(OH)2D3) receptor, regulates the NF-κB and STAT3 pathways, and participates in DNA repair processes and cytoskeletal remodeling. Recent studies have reported ERp57 overexpression in various human cancers, and altered expression and aberrant functionality of ERp57 are associated with cancer growth and progression and changes in the chemosensitivity of cancers. ERp57 may become a potential biomarker and therapeutic target to combat cancer development and chemoresistance. Here, we summarize the available knowledge of the role of ERp57 in cancer and the underlying mechanisms.

show abstract

Section: Clinical Implications Of Erp57 In Cancermentioning

confidence: 90%